Trials / Withdrawn
WithdrawnNCT00422110
A Study to Evaluate the Efficacy and Safety of Seletracetam in Adult Patients With Refractory Partial Onset Seizures
A Phase IIb/III, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Seletracetam as Adjunctive Treatment in Subjects (≥16 to 70 Years Old) With Refractory Partial Onset Seizures.
- Status
- Withdrawn
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 16 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the effectiveness and safety of seletracetam when it is used in addition to other anti-epileptic medications by patients with partial onset seizures. It will also help to determine the best dose to use.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Seletracetam |
Timeline
- Start date
- 2008-05-01
- First posted
- 2007-01-15
- Last updated
- 2012-05-28
Source: ClinicalTrials.gov record NCT00422110. Inclusion in this directory is not an endorsement.